Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients into the United States

CPA Applauds Trump Administration for Advancing Section 232 Action on Pharmaceutical Imports to Strengthen U.S. Manufacturing and Supply Chain Security

WASHINGTON, D.C. — The Coalition for a Prosperous America (CPA) today applauded the Trump administration for advancing Section 232 action on pharmaceutical imports, a critical step toward strengthening domestic production of pharmaceuticals and active pharmaceutical ingredients (APIs) and improving U.S. health security.The proclamation recognizes that the United States remains heavily dependent on foreign supply chains for pharmaceuticals and th…

Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients into the United States

BY THE PRESIDENT OF THE UNITED STATES OF AMERICA A PROCLAMATION 1.  The Secretary of Commerce (Secretary) recently transmitted to me a report on his

New Pharmaceutical Tariffs and MFN Policy: What It Could Mean for Patients

New Pharmaceutical Tariffs and MFN Policy: What It Could Mean for Patients April 3, 2026 The Administration has proposed new tariffs on pharmaceutical products and ingredients through a presidential action issued pursuant to a Section 232 investigation under the Trade Expansion Act. The policy is linked to efforts to encourage “most favored nation” (MFN) pricing agreements betw…

Trump Pharma Tariffs: Wrong Rx for U.S. Patients, Manufacturing, and Innovation

The Trump administration’s Section 232 pharmaceutical tariffs will needlessly raise drug costs, harm U.S. patients, and undermine both domestic manufacturing and global biopharmaceutical innovation, while better policy options exist to strengthen the industry without these damaging side effects.

AAM applauds 232 Investigation Executive Order on Pharmaceuticals

WASHINGTON  — The Association for Accessible Medicines has applauded the proclamation signed today by President Trump announcing the final results of a Section 232 investigation into possible tariffs and trade issues concerning pharmaceuticals. The investigation started in April of last year.“The generics and biosimilars industry applaud the Administration for recognizing the unique aspects of our industry’s supply chain and exempting generic an…